Teva Transfers Prostate Cancer Treatment Resistance Drug Back to OncoGenex

Teva Transfers Prostate Cancer Treatment Resistance Drug Back to OncoGenex
OncoGeneX Pharmaceuticals, Inc., a leader in the development of novel therapeutics that target important mechanisms of treatment resistance in cancer, has just announced it has signed an initial agreement contract with Teva Pharmaceutical Industries Ltd. to reclaim rights to custirsen, an experimental drug currently undergoing Phase III clinical testing as a potential treatment for lung

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *